Physician profile
William Kyle Vincent
NPI 1609296813
$3,171.38
in general payments reported to CMS, 2019-2025
28 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $511 · 2021: $810 · 2022: $460 · 2023: $86.47 · 2024: $246 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $638.62 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $590.68 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $194.19 | 2020-2024 | Mounjaro, Jardiance |
| Amgen INC. | $191.73 | 2019-2025 | Repatha, Otezla |
| Abbvie INC. | $188.30 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $173.35 | 2019-2022 | |
| Amarin Pharma, INC. | $141.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $140.19 | 2019-2025 | Arexvy, Shingrix |
| Allergan, INC. | $108.44 | 2019-2020 | |
| Pfizer INC. | $107.40 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $100.59 | 2019-2022 | |
| Abbott Laboratories | $85.35 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $70.25 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $62.30 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.76 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $56.46 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $43.96 | 2024-2025 | Cologuard Collection Kit |
| Alk-Abello, INC | $28.15 | 2025 | Neffy |
| Viiv Healthcare Company | $26.52 | 2025 | Apretude |
| Neotract INC. | $22.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.92 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.35 | 2021 | |
| Reprise Biomedical, INC. | $19.13 | 2025 | Miro3d |
| Ibsa Pharma INC. | $18.03 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.40 | 2021 | |
| Cequr Corporation | $16.01 | 2024 | Cequr Simplicity |
| Scilex Pharmaceuticals INC. | $14.61 | 2019 | |
| Eisai INC. | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.